Engen Bio
Pharmaceuticals, 61 Avondale Ave, REDWOOD CITY, California, 94062, United States, 1-10 Employees
Who is ENGEN BIO
EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal fl...
Read More
- Headquarters: 61 Avondale Ave, REDWOOD CITY, California, 94062, United States
- Employees: 1-10
- Revenue: Under $1 Million
Industry: Pharmaceuticals
SIC Code: 2836
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ENGEN BIO
Answer: ENGEN BIO's headquarters are located at 61 Avondale Ave, REDWOOD CITY, California, 94062, United States
Answer: ENGEN BIO's official website is https://engenbio.com
Answer: ENGEN BIO's revenue is Under $1 Million
Answer: ENGEN BIO's SIC: 2836
Answer: ENGEN BIO has 1-10 employees
Answer: ENGEN BIO is in Pharmaceuticals
Answer: ENGEN BIO contact info: Phone number: Website: https://engenbio.com
Answer: EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strainsincluding those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemicon a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (20192030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent needbut the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month